{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'If vomiting occurs shortly after the olaparib tablets are swallowed, the dose should only be', 'replaced if all of the intact tablets can be seen and counted. Should any patient enrolled on the', 'study miss a scheduled dose for whatever reason (e.g., as a result of forgetting to take the', 'tablets or vomiting), the patient will be allowed to take the scheduled dose up to a maximum', 'of 2 hours after that scheduled dose time. If greater than 2 hours after the scheduled dose', 'time, the missed dose is not to be taken and the patient should take their allotted dose at the', 'next scheduled time.', 'Dose Reductions', 'For guidance on dose reductions for management of AEs refer to Section 8.2.6.', 'For guidance on dose reductions when concomitant strong or moderate CYP3A inhibitors', 'cannot be avoided see Section 8.3.', 'Renal Impairment', \"If subsequent to study entry and while still on study therapy, a patient's estimated CrCl\", 'falls below the threshold for study inclusion (>51 ml/min), retesting should be performed', 'promptly.', 'A dose reduction is recommended for patients who develop moderate renal impairment', '(calculated creatinine clearance by Cockcroft-Gault equation or based on a 24 hour urine test', 'of between 31 and 50 ml/min) for any reason during the course of the study: the dose of', 'olaparib should be reduced to 200mg BD.', 'Because the CrCl determination is only an estimate of renal function, in instances where the', 'CrCl falls to between 31 and 50 mL/min, the investigator should use his or her discretion in', 'determining whether a dose change or discontinuation of therapy is warranted.', 'Olaparib has not been studied in patients with severe renal impairment (creatinine clearance', 'VI 30 ml/min) or end-stage renal disease; if patients develop severe impairment or end stage', 'disease it is recommended that olaparib be discontinued.', '8.2.3', 'Testosterone', 'Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected', 'intramuscularly are absorbed slowly from the lipid phase; thus, testosterone enanthate or', 'testosterone cypionate can be given at intervals of two to four weeks. These two forms of', 'testosterone exhibit identical pharmacokinetic properties and may be used interchangeably in', 'this study based on availability at the pharmacy [54]. These agents are administered as', 'intramuscular injections given deep in the gluteal muscle. They should not be given', 'intravenously. Testosterone cypionate is in cottonseed oil with benzyl alcohol as a', 'preservative. Testosterone enanthate is in sesame oil with chlorobutanol as a preservative.', '59(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding', 'globulin, and about 2 percent is free. Generally, the amount of this sex-hormone binding', 'globulin in the plasma will determine the distribution of testosterone between free and bound', 'forms, and the free testosterone concentration will determine its half-life.', 'About 90 percent of a dose of testosterone is excreted in the urine as glucuronic and sulfuric', 'acid conjugates of testosterone and its metabolites; about 6 percent of a dose is excreted in the', 'feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the', 'liver. Testosterone is metabolized to various 17-keto steroids through two different pathways.', 'The half-life of testosterone enanthate is approximately 4.5 to 8 days, and has been shown to', 'consistently result in supraphysiologic serum T levels following an intramuscular dose of', '>250 mg (Figure 12) [54].', 'Injection Interval', '1 week', '80', '60', '40', '20', '0', '80', '4 week', '60', '40', '20', '0', '0', '2', '4', '6', '8', '10', '12', '14', '16', 'Time (weeks)', 'Figure 12: Modeled T Kinetics with different T enanthate dosing schedules (250 mg IM). Dashed line', 'indicates physiologic T range (adapted from Nieschlag, et al[54]).', 'Testosterone Precautions', '1. Patients with benign prostatic hypertrophy may develop acute urethral obstruction.', 'Priapism or excessive sexual stimulation may develop.', '2. Oligospermia may occur after prolonged administration or excessive dosage.', '3. Testosterone Cypionate and Testosterone Enanthate should not be used', 'interchangeably with testosterone propionate because of differences in duration of', 'action.', '4. Testosterone Cypionate and Testosterone Enanthate are not for intravenous use.', 'Drug interactions', '60(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}